| |
HR (95% CI)
|
|---|
|
Unadjusted
|
Model 1a
|
Model 2a
|
Model 3a
|
|---|
|
FPG tertiles
|
|
Q1 (referent)
|
–
|
–
|
–
|
–
|
|
Q2
|
0.99 (0.78–1.27)
|
1.00 (0.78–1.29)
|
1.00 (0.77–1.30)
|
0.98 (0.75–1.26)
|
|
Q3
|
1.82 (1.46-2.26)†
|
1.81 (1.44-2.26)†
|
1.80 (1.43-2.27)†
|
1.76 (1.39-2.21)†
|
|
HbA1C tertiles
|
|
Q1 (referent)
|
–
|
–
|
–
|
–
|
|
Q2
|
1.75 (1.31–3.79)†
|
1.78 (1.34–2.36)†
|
1.79 (1.34–2.39)†
|
1.72 (1.29–2.28)†
|
|
Q3
|
2.92 (2.24–3.79)†
|
2.85 (2.18–3.73)†
|
2.89 (2.20–3.80)†
|
2.70 (2.05–3.54)†
|
|
TyG tertiles
|
|
Q1 (referent)
|
–
|
–
|
–
|
–
|
|
Q2
|
1.42 (1.09–1.86)‡
|
1.46 (1.11–1.92)‡
|
1.46 (1.01–1.92)§
|
1.33 (1.01–1.76)§
|
|
Q3
|
2.80 (2.21–3.55)†
|
2.81 (2.20–3.60)†
|
2.85 (2.22–3.67)†
|
2.36 (1.82–3.07)†
|
|
FPG/TyGa
|
|
Low/low (referent)
|
–
|
–
|
–
|
–
|
|
Low/High
|
2.10 (1.56–2.83)†
|
2.21 (1.63–2.99)†
|
2.22 (1.63–3.03)†
|
1.89 (1.38–2.59)†
|
|
High/Low
|
1.41 (1.01–1.96)§
|
1.45 (1.03–2.04)§
|
1.43 (1.01–2.03)§
|
1.52 (1.07–2.15)§
|
|
High/High
|
2.83 (2.22–3.60)†
|
2.81 (2.19–3.60)
|
2.83 (2.20–3.65)†
|
2.48 (1.92–3.21)†
|
|
HbA1C/TyGa
|
|
Low/low (referent)
|
–
|
–
|
–
|
–
|
|
Low/High
|
2.13 (1.50–3.01)†
|
2.20 (1.54–3.13)†
|
2.18 (1.52–3.12)†
|
1.92 (1.33–2.77)†
|
|
High/Low
|
2.12 (1.52–2.95)†
|
2.12 (1.51–2.97)†
|
2.11 (1.50–2.97)†
|
2.28 (1.61–3.23)†
|
|
High/High
|
3.99 (3.01–5.29)†
|
3.93 (2.94–5.26)†
|
3.99 (2.98–5.36)†
|
3.79 (2.78–5.17)†
|
- FPG fasting plasma glucose, HbA1C Glycosylated haemoglobin, TyG triglyceride glucose, HR hazard ratio, CI confidence interval
- †P<0.001
- ‡P<0.01
- §P<0.05
- aThe log-rank test and backward stepwise selection methods in a Cox proportional hazards regression model was performed; Model 1: adjusted for age, sex, BMI; Model 2: Model 1 + current smoker, hypertension, previous MI, previous stroke, previous PCI, previous CABG, ACS status; Model 3: Model 2 + non-HDL-C, lipid-lowering and antidiabetes medication use. Median HbA1C: 6.1%, median FBG: 6.19 mmol/L, median TyG:8.92
